clonidine has been researched along with Hypertrophy in 2 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seven-month-old, lean male SHHF/Mcc-cp rats, a model of spontaneous hypertension, progressive renal dysfunction, and congestive heart failure (CHF), were treated with either clonidine (CL) or enalapril (EN) or received no treatment (CON) for 20 weeks." | 3.68 | Effects of enalapril and clonidine on glomerular structure, function, and atrial natriuretic peptide receptors in SHHF/Mcc-cp rats. ( Hamlin, RL; Jenkins, JE; Jurin, RR; McCune, SA; Radin, MJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moss, JR | 1 |
| Cofer, S | 1 |
| Hersey, S | 1 |
| Goudy, S | 1 |
| Werkhaven, J | 1 |
| Swanson, E | 1 |
| Mantle, C | 1 |
| Stowell, N | 1 |
| Byrne, D | 1 |
| Wang, L | 1 |
| Labadie, R | 1 |
| Radin, MJ | 1 |
| Jenkins, JE | 1 |
| McCune, SA | 1 |
| Jurin, RR | 1 |
| Hamlin, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Tonsillectomy Pain Reduction Study, a Randomized, Placebo Controlled, Double-Blind Clinical Trial Using Clonidine and Local Anesthetics[NCT00678379] | Phase 3 | 120 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The median number of intravenous fentanyl doses administered in the PACU due to pain (NCT00678379)
Timeframe: in recovery room
| Intervention | number of doses (Median) |
|---|---|
| Normal Saline | 3.0 |
| Lidocaine (1%) + Bupivacaine 0.5% | 3 |
| Lidocaine 1% + Bupivacaine o.5% + Clondine 25mcg | 3 |
The total number of intravenous fentanyl doses given PACU which will be compared between the three randomized groups (arms) (NCT00678379)
Timeframe: Post-operative thru day 7
| Intervention | number of doses (Median) |
|---|---|
| Normal Saline | 12 |
| Lidocaine (1%) + Bupivacaine 0.5% | 12 |
| Lidocaine 1% + Bupivacaine o.5% + Clondine 25mcg | 14 |
(NCT00678379)
Timeframe: Day of Surgery
| Intervention | minutes (Median) |
|---|---|
| Normal Saline | 122 |
| Lidocaine (1%) + Bupivacaine 0.5% | 111 |
| Lidocaine 1% + Bupivacaine o.5% + Clondine 25mcg | 120 |
Visual analog pain scale range is 0-10 with 0=no pain and 10 = worst pain ever (NCT00678379)
Timeframe: in recovery room; post-operative days 1,3,5 & 7
| Intervention | pain score (Mean) | ||||
|---|---|---|---|---|---|
| In recovery room | day 1 | day 3 | day 5 | day 7 | |
| Lidocaine (1%) + Bupivacaine 0.5% | 3 | 4 | 2.5 | 2 | 2 |
| Lidocaine 1% + Bupivacaine o.5% + Clondine 25mcg | 3 | 5 | 3 | 3 | 2 |
| Normal Saline | 3 | 3 | 3 | 3 | 2.5 |
The number and percent of patients whose post-operative diet has to a regular diet on post-operative days 1, 3, 5 & 7 (NCT00678379)
Timeframe: post-operative days 1,3,5 & 7.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| post-op day 1 | post-op day 3 | post op day 5 | post op day 7 | |
| Lidocaine (1%) + Bupivacaine 0.5% | 4 | 8 | 18 | 26 |
| Lidocaine 1% + Bupivacaine o.5% + Clondine 25mcg | 1 | 12 | 14 | 22 |
| Normal Saline | 7 | 18 | 21 | 24 |
The number and percent of patients whose post-operative diet has only advanced to a soft diet on post-operative days 1, 3, 5 & 7 (NCT00678379)
Timeframe: post-operative days 1,3,5 & 7.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| post-op day 1 | post-op day 3 | post op day 5 | post op day 7 | |
| Lidocaine (1%) + Bupivacaine 0.5% | 22 | 26 | 17 | 10 |
| Lidocaine 1% + Bupivacaine o.5% + Clondine 25mcg | 26 | 18 | 18 | 14 |
| Normal Saline | 26 | 18 | 13 | 13 |
The number and percent of patients whose post-operative diet has advanced to liquids only on post-op days 1, 3, 5 & 7 (NCT00678379)
Timeframe: post-operative days 1,3,5 & 7.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| post-op day 1 | post-op day 3 | post op day 5 | post op day 7 | |
| Lidocaine (1%) + Bupivacaine 0.5% | 33 | 13 | 10 | 11 |
| Lidocaine 1% + Bupivacaine o.5% + Clondine 25mcg | 30 | 23 | 19 | 10 |
| Normal Saline | 16 | 8 | 13 | 6 |
1 trial available for clonidine and Hypertrophy
| Article | Year |
|---|---|
Comparison of clonidine, local anesthetics, and placebo for pain reduction in pediatric tonsillectomy.
Topics: Adenoids; Adolescent; Age Factors; Analgesics; Anesthetics, Local; Bupivacaine; Child; Child, Presch | 2011 |
1 other study available for clonidine and Hypertrophy
| Article | Year |
|---|---|
Effects of enalapril and clonidine on glomerular structure, function, and atrial natriuretic peptide receptors in SHHF/Mcc-cp rats.
Topics: Animals; Atrial Natriuretic Factor; Binding Sites; Clonidine; Cyclic GMP; Enalapril; Hypertension; H | 1992 |